J INTERN MED: Atrial fibrillation associated with the use of oral anticoagulants after ischemic stroke in cancer patients

Over the past decade, the number of patients with atrial fibrillation (AF) with oral anticoagulants (OAC) has increasedIn a recent study published in Journal of Internal Medicine, an authoritative journal of the field of internal medicine, researchers aim to describe the time trend of using OAC for secondary prevention in AF and active cancer patients after ischemic strokeA cross-sectional and cohort study of patients with active cancer (n?1518) and non-cancer (n-50953) at the Swedish National Registry, all of whom had had ischemic stroke between 1 July 2005 and 30 December 2017 and were discharged with AFThe researchers compared prescriptions and dispensing before and after the adoption of non-vitamin K OAC (NOACs) at the end of 2011, and used logistic and Cox regression to analyze the correlation with OAC, and adjusted for hospital aggregation and competitive death riskthe proportion of cancer patients with AF and OAC when discharged from hospitalischemic stroke increased by 40.2% after 2011, compared with 69.3% of non-cancer patients during the same periodThe risk of stroke and bleeding in patients with and without cancer remained similarIn the second year, cancer patients took OAC (43.8 percent vs64.5 percent) and no non-cancer patients took OAC (46.0 percent vs74.9 percent), and cancer patients took OAC or tested for significantly longer median spending (94 days vs30 days)thus shows that after the introduction of NOAC, the use of OAC treatment after stroke in AF-associated with active cancer patients has increased